Evaluating biological aging markers in Hodgkin's lymphoma patients
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
NA · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06761274
This study is trying to see if certain biological markers can help us understand how aging affects people with Hodgkin's lymphoma who are in remission or newly diagnosed.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna (other) |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06761274 on ClinicalTrials.gov |
What this trial studies
This study investigates epigenetic and inflammatory markers associated with accelerated biological aging in patients with Hodgkin's lymphoma. It focuses on individuals who are either in complete remission for at least two years after first-line therapy or newly diagnosed with advanced stages of the disease. The research involves analyzing peripheral blood samples to understand the long-term health implications and risks of secondary malignancies in these patients. The study is exploratory and aims to provide insights into the biological aging processes in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with Hodgkin's lymphoma in complete remission for at least two years or newly diagnosed patients requiring first-line therapy.
Not a fit: Patients with concomitant second neoplasms will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for long-term survivors of Hodgkin's lymphoma.
How similar studies have performed: While this approach is exploratory, similar studies have shown promise in understanding the long-term effects of cancer treatments on biological aging.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma * Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy * Patients of both sexes aged ≥ 18 years at enrollment * Signature of informed consent Exclusion Criteria: * Concomitant second neoplasm
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Italy (RECRUITING)
Study contacts
- Principal investigator: Pier Luigi Zinzani, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Pier Luigi Zinzani, MD
- Email: pierluigi.zinzani@unibo.it
- Phone: +390512144042
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hodgkin Lymphoma in Remission, epigenetic markers